Biotech Values

[mcbio]

At the end of the day, I think a not unlikely outcome is that MNTA gets a couple percent royalty on sales by Amphastar and Teva if the latter ever get approval.

What are the driving factors behind just receiving a couple percent royalty on sales versus an outright permanent injunction of the competitor's generic? With the former, it's like there's a small acknowledgement of infringement whereas in the latter it's much more clear. But, what is the fine line between these two outcomes and what drives whether one or the other is ultimately decided upon? This obviously has huge implications for MNTA because the latter outcome would validate their IP and would probably go a long way in ensuring that MNTA has the sole generic Lovenox on the market for a long time.